DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Catapres (Clonidine Hydrochloride) - Summary

 
 



CATAPRES SUMMARY

Catapres®
(clonidine hydrochloride USP)

CATAPRES® (clonidine hydrochloride USP) is a centrally acting alpha-agonist hypotensive agent available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg and 0.3 mg. The 0.1 mg tablet is equivalent to 0.087 mg of the free base.

CATAPRES® (clonidine hydrochloride USP) is indicated in the treatment of hypertension. CATAPRES may be employed alone or concomitantly with other antihypertensive agents.


See all Catapres indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Catapres (Clonidine)

Effect of oral low dose clonidine premedication on postoperative pain in patients undergoing abdominal hysterectomy: a randomized placebo controlled clinical trial. [2013]
CONCLUSION: A single oral 100 microg dose of clonidine administered 2 hours

Prophylactic midazolam and clonidine for emergence from agitation in children after emergence from sevoflurane anesthesia: a meta-analysis. [2013]
sevoflurane anesthesia... CONCLUSIONS: This meta-analysis suggests that prophylactic administration of

Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts. [2012]
BACKGROUND: Impulsivity refers to a wide spectrum of actions characterized by quick and nonplanned reactions to external and internal stimuli, without taking into account the possible negative consequences for the individual or others, and decision-making is one of the biologically dissociated impulsive behaviors...

The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. [2012]
BACKGROUND: The management of withdrawal absorbs substantial clinical efforts in opioid dependence (OD)... CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Preliminary results elucidate neurobiological mechanisms of OD and support the utility of controlled studies on a novel VLNTX + low-dose clonidine combination for the management of opioid withdrawal.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. [2011.10.10]
PURPOSE: Therapies for breast cancer may induce hot flashes that can affect quality of life. We undertook a double-blind, placebo-controlled trial with the primary objective of comparing the average daily hot flash scores in the twelfth week among patients treated with venlafaxine, clonidine, and placebo. Additional analyses of the hot flash score over the full 12 weeks of treatment were performed... CONCLUSION: Venlafaxine and clonidine are effective treatments in the management of hot flashes in patients with breast cancer. Venlafaxine resulted in a more immediate reduction of hot flash scores when compared with clonidine; however, hot flash scores at week 12 were lower in the clonidine group than in the venlafaxine group.

more studies >>

Clinical Trials Related to Catapres (Clonidine)

Epidural Fentanyl-bupivacaine Versus Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor [Not yet recruiting]
Epidural analgesia is widely regarding as the most effective analgesic strategy for labor pain. Modern practice is to utilize dilute local anesthetics as a continuous infusion along with an opioid, e. g., our common "recipe" of 12 ml/hr of 0. 0625% bupivacaine with 2 micrograms/ml fentanyl, after the initial dose to maintain patient comfort until delivery. This dose of the infusion often provides adequate comfort without interfering with the mobility of the patient and her ability to effectively push during delivery. However, this low dose epidural infusion strategy often results in recurrence of pain after an initial pain free period.

This breakthrough pain is treated by administering small boluses of analgesics via the epidural catheter. The pain occurring in labor is initially of visceral origin and is mediated by pain fibers originating from the low thoracic and upper lumbar segments of the spinal cord. As labor progresses to the late first phase (also known as transitional stage), pain sensations originating from the distension of the pelvic floor, vagina and perineum adds a somatic component to labor pain. This type of breakthrough pain is often difficult to treat.

Although requests from patients to alleviate late stage breakthrough pain are common, no one knows the most effective strategy for pain management in this stage of labor. This study is designed to compare the efficacy of two treatments for controlling late first stage breakthrough pain during labor with an epidural infusion in place: clonidine-bupivacaine versus fentanyl-bupivacaine.

Women who have labor epidural analgesia in place will be enrolled to be randomized if and when they present with breakthrough pain in the late first stage or second stage of labor (≥ 8 cm dilated). They will receive 8 ml of a solution containing 10 mg bupivacaine and 75 micrograms of either fentanyl (an opioid or "narcotic") or clonidine (an "alpha-2 agonist known to be effective as an epidural analgesic).

Pain relief, labor progress and outcome will be assessed to compare fentanyl versus clonidine.

It is the hypothesis of this study that clonidine added to bupivacaine is a better analgesic than fentanyl added to bupivacaine for breakthrough pain in advanced labor.

The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children [Recruiting]
Some of the children who suffer acute burn injury do not have adequate pain and anxiety management with the current regimen of scheduled opiates (morphine) and benzodiazepines (lorazepam). Other children have significant side effects or contraindications, such as constipation or over sedation, when taking these medications. Clonidine is known to reduce the need for morphine in the management of postoperative pain. The addition of clonidine to the pharmacological treatment of burn wound pain offers a possible adjunct to the standard opiate and benzodiazepines regimen. Clonidine has been used in children in both on a short-term basis (such as postoperative pain management) and on a long-term basis (such as the treatment of attention deficit hyperactivity disorder (ADHD)). This study tests the hypothesis that clonidine in a dose of 5 ug/kilo every 8 hours will be a useful adjunct to the management of pain and anxiety in the acutely burned child. All children will be treated by protocol with morphine (0. 03mg/kilo) q4hr prn pain and lorazepam (0. 03 mg/kilo) q 4 hours prn anxiety. In addition, after informed consent is obtained the children will be randomized to the addition clonidine or placebo. Pain and anxiety will be assessed using standard instruments blind to the medication being used on a daily basis Also the total dose of morphine and lorazepam during the 10 days of added clonidine or placebo will be recorded.. The pain rating, anxiety ratings, total morphine dose, and total lorazepam dose will be compared between the placebo and clonidine groups with a Student's t test. Once the blind is broken the child will be allowed to remain on the clonidine if it is beneficial. The second year of the grant will expand the age groups down to younger children and also begin to gain information about the effect of clonidine on the hypermetabolic state secondary to burn injury.

PeriOperative ISchemic Evaluation-2 Trial [Recruiting]
Major surgeries not involving the heart are common, and major heart problems during or after such surgeries represent a large population health problem. Few treatments to prevent heart problems around the time of surgery have been tested. There is encouraging data suggesting that small doses of Acetyl-Salicylic Acid (ASA) and Clonidine, which are two medications, given individually for a short period before and after major surgeries may prevent major heart problems. The POISE-2 Trial is a large international study to test if ASA and Clonidine can prevent heart attacks and deaths from heart problems around the time of surgery.

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants [Not yet recruiting]
Thousands of critically ill infants (and children) are exposed to opioids and benzodiazepines to achieve sedation and analgesia as part of routine care in neonatal and pediatric intensive care units. While the use of these agents are undisputedly beneficial in reducing pain and anxiety, improving ventilation, reducing pulmonary vascular resistance and improving outcomes; the consequence is often the development of tolerance and

physiologic dependence - similar to prenatal exposure from these same classes of drugs. The

investigators have recently reported the results of randomized placebo control trial showing that the addition of clonidine (central alpha 2 agonist) to tapering doses of opioids was efficacious and safe in treating opioid dependence in infants who had moderate to severe neonatal abstinence syndrome from prenatal drug exposure to opioids. Currently, the investigators propose to perform a double-blind, randomized placebo control trial in a cohort of critically ill infants without prenatal drug exposure at Johns Hopkins Hospital to test the overall hypothesis that early addition of clonidine to a cohort of critically ill neonates on mechanical ventilation who are receiving opioids and benzodiazepines for analgesia and sedation will be efficacious and safe in reducing both the incidence and severity of withdrawal symptoms (NICU-NAS); as well as, reducing the time to complete sedative and analgesic drug detoxification. The hypothesis will be tested by addressing 2 specific aims that will determine: 1) the efficacy and safety of clonidine in critically ill infants, and 2) pharmacokinetics and pharmacodynamics using population-based pharmacokinetics in this vulnerable infant population who have only been exposed to these drugs as part of their routine care. Many "standard of care practices" are incorporated in neonatal and pediatric care prior to evidence based studies. This proposal will fill a much needed gap in translating what the investigators have learned about basic mechanisms mediating dependence and withdrawal to proven therapies for vulnerable pediatric populations.

Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) [Recruiting]
The purpose of this study is to determinate the effect of a pre-treatment with centrally acting alpha2-receptor agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that clonidine will attenuate the subjective and cardiovascular response to MDMA.

more trials >>

Reports of Suspected Catapres (Clonidine) Side Effects

Hypertension (8)Weight Decreased (7)Hair Texture Abnormal (7)DRY Mouth (7)Decreased Appetite (7)Hypotension (7)Anxiety (7)Drug Ineffective (6)Headache (6)Blood Pressure Increased (6)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 4 ratings/reviews, Catapres has an overall score of 6.75. The effectiveness score is 5.50 and the side effect score is 8.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Catapres review by 52 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   one tab twice daily taken twice daily for the period of since 2007 to current
Other conditions:   hot flashes
Other drugs taken:   lisinopril/hctz 20-12.5 tab
  
Reported Results
Benefits:   (clonidine)It assisted in lowering my blood pressure by causing me to have a more voluminous (not more frequent)urination,when urged.Also,it aided in- depressing my agonizing hot flashes.They came at sequential intervals at time of menses and would last in that manner until completion of menses.Thereafter,they were intermitten daily.
Side effects:   If this is the side effect.It would be, soon after taking the meds,There is a timed-released drowsy effect that occurs,within a matter of 15-20 minutes.This is the only so-called side effect that I've experienced.But,I guess,it is a matter of where you are and what's on your agenda during this side-effect.
Comments:   I'm not completely sure what to write here,that would consist of fifty words.I take (Clonidine)-0.1mg 1 tab twice daily and (Lisinopril/HCTZ)-20mgs.12.5 1tab,twice daily.I've learned to take them with food.Earlier,when introduced to these meds,upon attending a Drs. appointment and having my blood pressure checked,the reading would be high and I felt no internal or external symptoms.The inquiry would be have you taken your meds? and I had.So,it was suggested that I try administering them with food.Thereafter,no more high readings and entered a normalized phase.

 

Catapres review by 59 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Hot Flashes
Dosage & duration:   0.1 mg taken 1x a day at bedtime for the period of Once
Other conditions:   Hypothyroidism
Other drugs taken:   Synthroid
  
Reported Results
Benefits:   It was supposed to stop the hot flashes that were keeping me awake at night.
Side effects:   Left me extremely sleepy the next day to the point I had to lay down an hour after I got up and I noticed no real difference in the hot flashes.
Comments:   I wanted to stop hot flashes without going on HRT medication. My doctor recommended trying Clonidine

 

Catapres review by 59 year old female patient

  Rating
Overall rating:  
Effectiveness:   Ineffective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Hot Flashes
Dosage & duration:   0.1 mg taken 1x a day at bedtime for the period of Once
Other conditions:   Hypothyroidism
Other drugs taken:   Synthroid
  
Reported Results
Benefits:   It was supposed to stop the hot flashes that were keeping me awake at night.
Side effects:   Left me extremely sleepy the next day to the point I had to lay down an hour after I got up and I noticed no real difference in the hot flashes.
Comments:   I wanted to stop hot flashes without going on HRT medication. My doctor recommended trying Clonidine

See all Catapres reviews / ratings >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014